awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16
Q33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
P2860
Q33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33577870-E366F4C9-55E9-42DE-AC65-8452B3D25E16
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
93a7f1d529ed7877ed9c8f690a6fa794e42d0188
P2860
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.